SecBot SecBot

BGLC

BioNexus Gene Lab Corp
Nasdaq· Services-Medical Laboratories· Inc. WY· CIK 0001737523 Healthcare & Medical Devices
$1.16 −0.03 (−2.52%)
Oct 26 4:00 PM ET · prev $1.19
Market cap
$3.5M
Nano cap
1 year
−77.1%
from $5.06 · Oct 27
30 days
−10.8%
from $1.30
52-week range
$1.16–5.48
at the low
Avg volume 20D
9.0K
Oct 1 spike 40.8K
Short interest
🔒 Subscribers only
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
3
analyzed by SecBot
SecBot read MIXED 2 reports · 90 days
Balance 0 bearish · 0 bullish · 1 mixed · 1 neutral oldest → newest, height = score
Avg score ·High conf. 1/2
Strongest MIXED BioNexus Gene Lab Corp. (BGLC) entered into a definitive agreement with Ruanyun Edai Technology Inc. (RYET)…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q2 2026: 0 added (0 new), 1 trimmed or exited.

  • TrendDOWNTREND

    17% below its 50-day average. New closing low $1.16 on Oct 26.

  • SocialQUIET

    No Reddit mentions this week. Last mention Oct 5.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
UBS Group AGTRIM101$197.00
UBS Group AGNEAR_EXIT4$1.00
UBS Group AGADD109,632$30.7K

Quarterly 13F filings are due 45 days after each quarter ends.

Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Mar 11, 2026
Press release
BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard™ MRD Platform
KUALA LUMPUR, Malaysia, March 11, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ: BGLC) today announced that, in connection with its…
Reddit
Recent posts
r/pennystocks Neutral 22d ago
$RYET - $9.3M-$9.5M H1 Revenue, an $880K AI Deployment and a New 10 percent Royalty Deal
1 upvotes · 1 comments
All social signals and their track records

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Aug 13, 2026
Low Jook Yuen
Director
AWARD16,129 sh
Aug 13, 2026
Chong Set Fui
Chief Financial Officer
AWARD96,774 sh
Aug 13, 2026
Tan Lee Su-Leng
Chief Executive Officer
AWARD338,709 sh
Aug 13, 2026
Bin Abdul Hamid Muhammad Azrul
Director
AWARD32,258 sh
Aug 13, 2026
Yap Chee Keong
Director
AWARD32,258 sh

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 22, 2026 SEC
Fidelion Diagnostics Pte. Ltd., together with affiliated entities (Molecule Bio LLC, Rainy Morning Technology (Hong…
SC 13G — Impact 4/10
Oct 7, 2026 SEC
BioNexus Gene Lab Corp. (BGLC) entered into a definitive agreement with Ruanyun Edai Technology Inc. (RYET) for an…
8-K — Impact 6/10
Aug 13, 2026 Insider
Low Jook Yuen was granted 16,129 shares
Director
Aug 13, 2026 Insider
Chong Set Fui was granted 96,774 shares
Chief Financial Officer
Aug 13, 2026 Insider
Tan Lee Su-Leng was granted 338,709 shares
Chief Executive Officer
Jun 30, 2026 Inst.
UBS Group AG — TRIM
101 shares ($197.00)
Jun 5, 2026 SEC
BioNexus Gene Lab Corp. issued a press release highlighting its CEO's participation as a speaker at the 2026…
8-K — Impact 2/10
Mar 11, 2026 Other
BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard™ MRD Platform
KUALA LUMPUR, Malaysia, March 11, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ: BGLC) to

SecBot reports

3 filings · 0 bullish · 0 bearish · 1 mixed · 2 neutral
All BGLC filing & press-release reports (3)